RT Journal Article
T1 Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper
A1 Cortellini, Gabriele
A1 Nakonechna, Alla
A1 Barbaud, Annick
A1 Bavbek, Sevim
A1 Calogiuri, Gianfranco
A1 Doña, Inmaculada
A1 Kvedariene, Violeta
A1 Laguna Martinez, Jose Julio
A1 Liberati, Serena
A1 Pagani, Mauro
A1 Romano, Antonino
K1 Medicamentos - Efectos secundarios
K1 Plaquetas sanguíneas
K1 Aspirina
AB Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDsare aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs). The mostcommon reported reactions to these drugs are cutaneous, such as exanthemas associated with thienopyridine and urticaria/angioedema by aspirin, which can also induce respiratory symptoms. APDs other than aspirin, particularly ticlopidine, canalso cause hematologic reactions consisting mainly of isolated thrombocytopenia, agranulocytosis, and leukopenia. Immune-mediated reactions to aspirin are very rare. Few data suggest the usefulness of skin testing in patients with cutaneous reactionsto APDs other than aspirin, particularly clopidogrel. Therefore, the drug provocation test is the gold standard for diagnosing hy-persensitivity to APDs. Low-dose aspirin challenge (i.e., up to 150–180 mg) and aspirin desensitization have emerged as effective and safe approaches in patients with suspected or confirmed aspirin hypersensitivity who require aspirin therapy. Both, a shortcourse of oral glucocorticoids without interruption of clopidogrel treatment and desensitization, appears to be effective andsafe options in patients with cutaneous HSRs to clopidogrel. This position paper provides data and recommendations regardingthe characteristics of HSRs to APDs and related diagnostic procedures in order to make them as safe and effective as possible.Management and treatment options, including desensitization protocols, are also provided.
PB Wiley
YR 2025
FD 2025
LK https://hdl.handle.net/10630/40040
UL https://hdl.handle.net/10630/40040
LA eng
NO G. Cortellini, A. Nakonechna, A. Barbaud, et al., “ Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper,” Allergy (2025): 1–15, https://doi.org/10.1111/all.16663.
NO European Academy of Allergy and Clinical Immunology (EAACI)
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 31 ene 2026